Wednesday, November 4, 2026Updated every morning at 5:30 AM ET
NanotechProgress

Albumin-bound paclitaxel (Abraxane)

Abraxane is the cancer drug paclitaxel bound to albumin, a human blood protein, in the form of nanoparticles. Approved in 2005 for breast cancer that has spread, it was the first of a new class of albumin-bound nanomedicines.

News-Medical, 9 Jan 2005
Cancer drug in protein nanoparticles · how far it has got4/5Approved or on sale

How far from your life: You can get it now, though it may not be common yet.

Independently sourced

From lab to your life

Why it’s on step 4

  1. 1Lab discovery
  2. 2Working prototype
  3. 3Real-world testing
  4. 4Approved or on sale
  5. 5Everyday life

The rule

A regulator approved or cleared it where approval applies (the FDA, the EMA, a CE mark), or it is sold to the public or to customers beyond a trial.

  • The FDA approved Abraxane for breast cancer that has spread, the first of a new class of albumin-bound nanoparticle drugs. News-Medical, 9 Jan 2005

The short version

What you need to know

Why it matters

The older form of paclitaxel is dissolved in a solvent that can cause dangerous allergic reactions, so patients first need steroids. The nanoparticle form doesn't need them.

News-Medical, 9 Jan 2005
Is it really nano?

Truly nano

The protein nanoparticle replaces the harsh solvent the older drug needs; that is the whole difference.

News-Medical, 9 Jan 2005
Where you’ll find it

Given in cancer clinics, first approved for breast cancer that has spread.

News-Medical, 9 Jan 2005
Who’s behind it

Developed by American Pharmaceutical Partners; now sold by Bristol Myers Squibb

On the record

Every step, dated

Newest first. Company-reported means the only source so far is the company itself.

  1. Approval

    The FDA approved Abraxane for breast cancer that has spread, the first of a new class of albumin-bound nanoparticle drugs.

    News-Medical, 9 Jan 2005